MedPath

A randomized controlled trial on radiofrequency ablation using variable and fixed electrodes for the treatment of malignant hepatic tumors

Not Applicable
Conditions
malignant hepatic tumors
Registration Number
JPRN-UMIN000032072
Lead Sponsor
Juntendo University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
210
Inclusion Criteria

Not provided

Exclusion Criteria

(i) tumor not visualized by ultrasonography or not accessible percutaneously (ii) total bilirubin level of 3.0 mg/dl or higher (iii) platelet count of less than 50x10 9/l or prothrombin activity of less than 50% (iv) refractory ascites (v) enterobiliary reflux

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary endpoints are the incidence of adverse events and the short-term treatment response based on contrast-CT using the modified RECIST criteria following one session of radiofrequency ablation.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath